Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Saved in:
| Title: | Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. |
|---|---|
| Authors: | Monge S; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBER on Infectious Diseases, Madrid, Spain., Humphreys J; Epiconcept, Paris, France., Nicolay N; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Braeye T; Sciensano, Elsene, Belgium., Van Evercooren I; Sciensano, Elsene, Belgium., Holm Hansen C; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Emborg HD; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Sacco C; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden., Mateo-Urdiales A; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy., Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health, Madrid, Spain., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health, Madrid, Spain., de Gier B; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., Hahné S; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., Meijerink H; Norwegian Institute of Public Health (NIPH), Oslo, Norway., Kristoffersen AB; Norwegian Institute of Public Health (NIPH), Oslo, Norway., Machado A; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal., Soares P; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal., Nardone A; Epiconcept, Paris, France., Bacci S; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Kissling E; Epiconcept, Paris, France., Nunes B; Epiconcept, Paris, France. |
| Corporate Authors: | VEBIS‐EHR Working Group |
| Source: | Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Apr; Vol. 18 (4), pp. e13292. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38654485 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Monge+S%22">Monge S</searchLink>; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBER on Infectious Diseases, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Humphreys+J%22">Humphreys J</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Nicolay+N%22">Nicolay N</searchLink>; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Braeye+T%22">Braeye T</searchLink>; Sciensano, Elsene, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+Evercooren+I%22">Van Evercooren I</searchLink>; Sciensano, Elsene, Belgium.<br /><searchLink fieldCode="AU" term="%22Holm+Hansen+C%22">Holm Hansen C</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Emborg+HD%22">Emborg HD</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Sacco+C%22">Sacco C</searchLink>; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Mateo-Urdiales+A%22">Mateo-Urdiales A</searchLink>; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Castilla+J%22">Castilla J</searchLink>; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez-Baz+I%22">Martínez-Baz I</searchLink>; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22de+Gier+B%22">de Gier B</searchLink>; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hahné+S%22">Hahné S</searchLink>; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meijerink+H%22">Meijerink H</searchLink>; Norwegian Institute of Public Health (NIPH), Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Kristoffersen+AB%22">Kristoffersen AB</searchLink>; Norwegian Institute of Public Health (NIPH), Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Machado+A%22">Machado A</searchLink>; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Soares+P%22">Soares P</searchLink>; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Nardone+A%22">Nardone A</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bacci+S%22">Bacci S</searchLink>; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Kissling+E%22">Kissling E</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Nunes+B%22">Nunes B</searchLink>; Epiconcept, Paris, France. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22VEBIS‐EHR+Working+Group%22">VEBIS‐EHR Working Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101304007%22">Influenza and other respiratory viruses</searchLink> [Influenza Other Respir Viruses] 2024 Apr; Vol. 18 (4), pp. e13292. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101304007 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1750-2659 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217502640%22">17502640 </searchLink><i>NLM ISO Abbreviation: </i>Influenza Other Respir Viruses <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38654485 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/irv.13292 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e13292 Titles: – TitleFull: Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Monge S – PersonEntity: Name: NameFull: Humphreys J – PersonEntity: Name: NameFull: Nicolay N – PersonEntity: Name: NameFull: Braeye T – PersonEntity: Name: NameFull: Van Evercooren I – PersonEntity: Name: NameFull: Holm Hansen C – PersonEntity: Name: NameFull: Emborg HD – PersonEntity: Name: NameFull: Sacco C – PersonEntity: Name: NameFull: Mateo-Urdiales A – PersonEntity: Name: NameFull: Castilla J – PersonEntity: Name: NameFull: Martínez-Baz I – PersonEntity: Name: NameFull: de Gier B – PersonEntity: Name: NameFull: Hahné S – PersonEntity: Name: NameFull: Meijerink H – PersonEntity: Name: NameFull: Kristoffersen AB – PersonEntity: Name: NameFull: Machado A – PersonEntity: Name: NameFull: Soares P – PersonEntity: Name: NameFull: Nardone A – PersonEntity: Name: NameFull: Bacci S – PersonEntity: Name: NameFull: Kissling E – PersonEntity: Name: NameFull: Nunes B IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2024 Apr Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1750-2659 Numbering: – Type: volume Value: 18 – Type: issue Value: 4 Titles: – TitleFull: Influenza and other respiratory viruses Type: main |
| ResultId | 1 |
